Nexium News and Research

RSS

Esomeprazole is a proton pump inhibitor (brand names Sompraz, Zoleri, Nexium, Lucen, Esopral; Axagon in Italy, Nexiam in Belgium and South Africa) developed and marketed by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the ''S''-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. However, this greater efficacy has been disputed, with some claiming it offers no benefit from its older form.

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment.

19 Sep 2023

The drug company that prospered without creating any drugs

The new drug looked so promising — except for that one warning sign.

13 Apr 2023

Common heart burn medication could lessen the effectiveness of lung cancer treatment

A common medication used to treat reflux, heart burn and ulcers could lessen the effectiveness of lung cancer immunotherapy drugs, according to new Flinders University research.

24 Nov 2021

$Investigational drug reduces heartburn severity in patients with refractory GERD$

Investigational drug reduces heartburn severity in patients with refractory GERD

An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.

26 Feb 2020

Study links use of acid reflux drugs with poorer concentration, memory in breast cancer survivors

Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect: impairment of breast cancer survivors' memory and concentration.

17 Jan 2020

Gastroesophageal reflux disease may affect nearly a third of U.S. adults every week

Gastroesophageal reflux disease (GERD), a digestive disorder that causes hearburn and other uncomfortable symptoms, may affect nearly a third of U.S. adults each week, and most of those who take certain popular medications for it still have symptoms, according to a new Cedars-Sinai study.

19 Dec 2019

Popular heartburn drug voluntarily recalled for carcinogen levels above FDA standards

The popular heartburn drug ranitidine, commonly known as Zantac, was voluntarily recalled due to the contamination of a human carcinogen that could potentially cause cancer. The recall includes oral tablets, capsules, and syrup.

27 Nov 2019

Potential side effects increase in children with use of common reflux aids, study shows

Proton Pump Inhibitors (PPIs) -- such as Prilosec, Protonix and Nexium, have long been one of the most prescribed medications in the country to aid in the reduction of stomach acid.

7 Nov 2019

Study links heartburn drugs to fatal cases of heart, kidney disease and gastrointestinal cancer

Extended use of popular drugs to treat heartburn, ulcers and acid reflux has been associated with an increased risk of premature death. However, little has been known about the specific causes of death attributed to the drugs.

30 May 2019

Common acid reflux drugs tied to elevated risk for kidney disease

Proton pump inhibitors, which include well-known brand names Prilosec, Nexium and Prevacid, are among the most commonly prescribed medications in the world. Approximately 10 percent of adults in the United States take these drugs for frequent heartburn, acid reflux and gastroesophageal reflux disease.

19 Feb 2019

Invasive surgery should be done for select patients with acid reflux, says study

As the number of Americans with acid reflux grows, a study by researchers at the University of Colorado Anschutz Medical Campus says invasive procedures to treat those who don't respond to medication should be done for select patients.

8 May 2018

Common acid reflux drugs linked to progression of chronic liver disease

Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease.

10 Oct 2017

Proton pump inhibitors linked to increased death risk

Proton pump inhibitors (PPIs) are one of the commonest agents prescribed for heart burn or acid reflux. These agents are available for purchase over-the-counter making them one of the most commonly used drugs that make around $10 billion in annual sales. PPIs work by reducing the production of the gastric acids in the stomach. There are several known risks associated with PPI use including complete stoppage of gastric acid production, risk of pneumonia, kidney disorders, bone fractures such as hip fractures etc.

5 Jul 2017

Longtime use of heartburn drugs linked to increased risk of death

Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia.

4 Jul 2017

Former pharma reps’ new mission: To school docs on high drug costs

As a drug salesman, Mike Courtney worked hard to make health care expensive. He wined and dined doctors, golfed with them and bought lunch for their entire staffs — all to promote pills often costing thousands of dollars a year.

8 Jun 2017

Prolonged use of popular heartburn drugs linked to silent, gradual kidney damage

Taking popular heartburn drugs for prolonged periods has been linked to serious kidney problems, including kidney failure.

22 Feb 2017

Common heartburn medications could decrease effects of chemotherapy in cancer patients

Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse.

16 Dec 2016

Chronic use of antacid drugs may speed up aging of blood vessels

Chronic use of some drugs for heartburn and gastroesophageal reflux (GERD) speeds up the aging of blood vessels, according to a published paper in Circulation Research, an American Heart Association journal.

11 May 2016

Acid suppression drugs frequently prescribed for high-risk newborns, study shows

Since 2006, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. Those medications - histamine-2 receptor antagonists, such as ranitidine (Zantac and others), and proton pump inhibitors, such as esomeprazole (Nexium and others) - were originally approved by the U.S. Food and Drug Administration for use in adults and older children.

27 Apr 2016

Camber Pharmaceuticals releases generic version of Nexium (Esomeprazole) capsules

Camber Pharmaceuticals is pleased to announce that it has launched Esomeprazole Magnesium Delayed-Release Capsules, 20 mg and 40 mg, which is the generic version of Nexium (Esomeprazole) capsules from AstraZeneca Pharmaceuticals. The product is indicated for the treatment of heartburn, gastroesophageal reflux disease (GERD), stomach ulcers, and for a damaged esophagus.

24 Sep 2015